These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

644 related articles for article (PubMed ID: 34906598)

  • 21. The NLRP3 inflammasome: contributions to inflammation-related diseases.
    Chen Y; Ye X; Escames G; Lei W; Zhang X; Li M; Jing T; Yao Y; Qiu Z; Wang Z; Acuña-Castroviejo D; Yang Y
    Cell Mol Biol Lett; 2023 Jun; 28(1):51. PubMed ID: 37370025
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The double sides of NLRP3 inflammasome activation in sepsis.
    Vigneron C; Py BF; Monneret G; Venet F
    Clin Sci (Lond); 2023 Mar; 137(5):333-351. PubMed ID: 36856019
    [TBL] [Abstract][Full Text] [Related]  

  • 23. POP1 inhibits MSU-induced inflammasome activation and ameliorates gout.
    de Almeida L; Devi S; Indramohan M; Huang QQ; Ratsimandresy RA; Pope RM; Dorfleutner A; Stehlik C
    Front Immunol; 2022; 13():912069. PubMed ID: 36225929
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacological Inhibition of the NLRP3 Inflammasome: Structure, Molecular Activation, and Inhibitor-NLRP3 Interaction.
    Ma Q
    Pharmacol Rev; 2023 May; 75(3):487-520. PubMed ID: 36669831
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Atherothrombosis and the NLRP3 inflammasome - endogenous mechanisms of inhibition.
    Satish M; Agrawal DK
    Transl Res; 2020 Jan; 215():75-85. PubMed ID: 31469975
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Regulation and Function of the Nucleotide Binding Domain Leucine-Rich Repeat-Containing Receptor, Pyrin Domain-Containing-3 Inflammasome in Lung Disease.
    Lee S; Suh GY; Ryter SW; Choi AM
    Am J Respir Cell Mol Biol; 2016 Feb; 54(2):151-60. PubMed ID: 26418144
    [TBL] [Abstract][Full Text] [Related]  

  • 27. NLRP3 inflammasome in cardiovascular diseases: Pathophysiological and pharmacological implications.
    Pellegrini C; Martelli A; Antonioli L; Fornai M; Blandizzi C; Calderone V
    Med Res Rev; 2021 Jul; 41(4):1890-1926. PubMed ID: 33460162
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cellular Models and Assays to Study NLRP3 Inflammasome Biology.
    Zito G; Buscetta M; Cimino M; Dino P; Bucchieri F; Cipollina C
    Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32560261
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting NLRP3 inflammasome for neurodegenerative disorders.
    Yao J; Wang Z; Song W; Zhang Y
    Mol Psychiatry; 2023 Nov; 28(11):4512-4527. PubMed ID: 37670126
    [TBL] [Abstract][Full Text] [Related]  

  • 30. NLRP3 Inflammasome-A Key Player in Antiviral Responses.
    Zhao C; Zhao W
    Front Immunol; 2020; 11():211. PubMed ID: 32133002
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of NLRP3 inflammasome in the pathogenesis of cardiovascular diseases.
    Liu D; Zeng X; Li X; Mehta JL; Wang X
    Basic Res Cardiol; 2018 Jan; 113(1):5. PubMed ID: 29224086
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of NLRP3 inflammasome in inflammatory bowel diseases.
    Tourkochristou E; Aggeletopoulou I; Konstantakis C; Triantos C
    World J Gastroenterol; 2019 Sep; 25(33):4796-4804. PubMed ID: 31543674
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The NLRP3 inflammasome in depression: Potential mechanisms and therapies.
    Xia CY; Guo YX; Lian WW; Yan Y; Ma BZ; Cheng YC; Xu JK; He J; Zhang WK
    Pharmacol Res; 2023 Jan; 187():106625. PubMed ID: 36563870
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Selective inhibition of NLRP3 inflammasome by designed peptide originating from ASC.
    Sušjan P; Lainšček D; Strmšek Ž; Hodnik V; Anderluh G; Hafner-Bratkovič I
    FASEB J; 2020 Aug; 34(8):11068-11086. PubMed ID: 32648626
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Posttranslational modifications of NLRP3 and their regulatory roles in inflammasome activation.
    Qin Y; Zhao W
    Eur J Immunol; 2023 Oct; 53(10):e2350382. PubMed ID: 37382218
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting the NLRP3 inflammasome in diabetic retinopathy: From pathogenesis to therapeutic strategies.
    Yang Y; Jiang G; Huang R; Liu Y; Chang X; Fu S
    Biochem Pharmacol; 2023 Jun; 212():115569. PubMed ID: 37100255
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Frontline Science: Specialized proresolving lipid mediators inhibit the priming and activation of the macrophage NLRP3 inflammasome.
    Lopategi A; Flores-Costa R; Rius B; López-Vicario C; Alcaraz-Quiles J; Titos E; Clària J
    J Leukoc Biol; 2019 Jan; 105(1):25-36. PubMed ID: 29601102
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and Pharmacology of the NLRP3 Inflammasome Inhibitor CP-456,773 (CRID3) in Murine Models of Dermal and Pulmonary Inflammation.
    Primiano MJ; Lefker BA; Bowman MR; Bree AG; Hubeau C; Bonin PD; Mangan M; Dower K; Monks BG; Cushing L; Wang S; Guzova J; Jiao A; Lin LL; Latz E; Hepworth D; Hall JP
    J Immunol; 2016 Sep; 197(6):2421-33. PubMed ID: 27521339
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Focus on the role of NLRP3 inflammasome in the pathology of endometriosis: a review on molecular mechanisms and possible medical applications.
    Irandoost E; Najibi S; Talebbeigi S; Nassiri S
    Naunyn Schmiedebergs Arch Pharmacol; 2023 Apr; 396(4):621-631. PubMed ID: 36542122
    [TBL] [Abstract][Full Text] [Related]  

  • 40. IAPP/amylin deposition, which is correlated with expressions of ASC and IL-1β in β-cells of Langerhans' islets, directly initiates NLRP3 inflammasome activation.
    Morikawa S; Kaneko N; Okumura C; Taguchi H; Kurata M; Yamamoto T; Osawa H; Nakanishi A; Zako T; Masumoto J
    Int J Immunopathol Pharmacol; 2018; 32():2058738418788749. PubMed ID: 30014749
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 33.